Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.

[powerpress]

Every year, many of the most important developments in cancer care are presented at ASCO. This year, we've got what I think is a very important year in lung cancer, with several practice-changing results/.

Dr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.

[powerpress]

Squamous Lung Cancer, Part 3: Treatment Audio Podcast